HOME >> MEDICINE >> NEWS
Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy

(PHILADELPHIA) -- The number of tumor cells circulating in the bloodstream of patients with metastatic, hormone-resistant, prostate cancer can predict how they will do with chemotherapy, according to results of an international trial. The findings, if backed by larger studies, could have important implications for designing personalized treatments for this very dangerous type of prostate cancer, the researchers say.

The team of scientists including first author Jose Moreno, M.D., clinical associate professor of urology at Jefferson Medical College of Thomas Jefferson University in Philadelphia and the Kimmel Cancer Center at Jefferson looked at circulating tumor cells (CTCs) in 240 men with metastatic prostate cancer that failed hormone-depletion therapy. They compared levels prior to chemotherapy and after two to five weeks of treatment. They found that those men with more than five tumor cells per blood sample had a worse prognosis than those who had fewer cells. One half of the patients with more than five CTCs lived at least 10 months, whereas half of the men with fewer tumor cells lived substantially longer 21 months.

Dr. Moreno presents the trials findings June 4, 2007 at the annual meeting of the American Society of Clinical Oncology in Chicago.

The results of the 65-site trial also showed that those patients who underwent chemotherapy and whose CTC number went down fared better and had a more favorable prognosis. That is, the level of response to chemotherapy was reflected in the CTC level, notes Dr. Moreno. The numbers held up even after up to 20 weeks of treatment. If chemotherapy doesnt reduce the CTC level, its information that enables the physician to change the drug regimen or perhaps stop treatment, he says.

Dr. Moreno notes that the prostate specific antigen has been a powerful biomarker for cancer presence and a useful way to gauge treatment effectiveness for years, though it has some flaws. He thinks that th
'"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
4-Jun-2007


Page: 1 2

Related medicine news :

1. Trial stops after stroke and mortality significantly reduced by blood
2. Trials underway for essential new TB vaccine
3. ENDEAVOR III Trial reports key findings on new-generation stent
4. NIH names Clinical Trial Units for the Microbicide Trials Network
5. Clinical Trials Units selected for newly restructured HIV/AIDS research networks
6. The Public Library of Science launches the new open access journal PLoS Clinical Trials
7. Trial shows vaccine against cervical cancer provides long-term protection
8. Trial shows malaria vaccine could protect young children from disease for 18 months
9. Trial demonstrates new drugs effectiveness against psoriasis
10. Trial at Jefferson shows new drug may help cancer patients who need stem cell transplants
11. Second implant of US Pilot Trial achieved

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/11/2018)... ... October 11, 2018 , ... The Danisco Foundation today has ... their fields recognized by DuPont Nutrition & Health for scientific excellence and a ... of food, nutrition and health. , This year’s medalists are: , ? DuPont ...
(Date:10/7/2018)... ... October 07, 2018 , ... Guruji Mahendra Trivedi ... affecting humanity at practical and spiritual levels. Founder of the Trivedi Effect®, Guruji ... ‘Special Prayers’, inspired by Navratri, is a mystical time when Divine Energy is ...
(Date:10/6/2018)... ... , ... Jose Rodriguez- Feliz M.D is a board–certified plastic ... known for their exclusivity, and luxurious lifestyle publication is privileged to present Dr. ... the Haute Living network. , Haute Beauty consists of a prominent collective ...
(Date:10/5/2018)... SULPHUR SPRINGS, Texas (PRWEB) , ... October 05, ... ... at the Cerner Health Conference (CHC) 2018, an annual conference on the latest ... technology, will host this year’s event Oct. 8-11 throughout downtown Kansas City, Missouri. ...
(Date:10/5/2018)... ... October 05, 2018 , ... Yisrayl Hawkins, Pastor and Overseer at The ... focuses on Prophecy written thousands of years ago, but written for this current generation ... with the Vatican and other leaders that he says, is taking place now. ...
Breaking Medicine News(10 mins):
(Date:10/16/2018)... Canada (PRWEB) , ... October 16, 2018 , ... ... innovative companies involved in the development and marketing of algae-based omega-3 products, Ben ... the 2018 Algae Biomass Summit in Houston, Texas on October 15. The title ...
(Date:10/13/2018)... , ... October 12, 2018 , ... ... are now open, welcoming applications from healthcare providers, students, trainees, and researchers worldwide. ... as well as microbiome sequencing and bioinformatics services. , “uBiome is thrilled to ...
(Date:10/11/2018)... ... October 11, 2018 , ... ... software for corporate law departments and law firms, today announced it is sponsoring ... visit booth 110 to learn how corporate legal departments are using smart data, ...
Breaking Medicine Technology:
Cached News: